Share information
281.20 €
+1.70 %
04/11/2026 13:21
+1.70 %
Open
High
Low
Volume
277.40 €
281.40 €
275.50 €
22,325
Latest News
04-Nov-2026
UCB advances its digital antibody engineering program with new Cradle collaboration
22-Oct-2026
Strong Performance Drives Further Upgrade to UCB’s 2026 Financial Guidance
19-Oct-2026
Transparency notification Wellington
16-Oct-2026
UCB announces U.S. FDA approval for ZILBRYSQ[®] (zilucoplan) autoinjector self-administration for adults living with generalized myasthenia gravis